Fusion protein · Inhibitor of neonatal Fc receptor (FCGRT) · developed by Argenx Bv
Efgartigimod alfa is a human IgG1-derived Fc fragment that binds the neonatal Fc receptor (FcRn) and blocks it from recycling IgG back into the circulation, reducing circulating IgG levels, including pathogenic autoantibodies. It is studied in myasthenia gravis, optic neuritis, and epidermolysis bullosa.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of May 13, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06765161 | Phase 3 | Myasthaenia Gravis | Recruiting | ARGX |
| NCT07011589 | Phase 1/2 | Epidermolysis Bullosa (EB) | Not yet recruiting | ARGX |
| NCT06453694 | Phase 2 | Optic Neuritis | Recruiting | ARGX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Dystrophic Epidermolysis BullosaEpidermolysis Bullosa (EB)Epidermolysis Bullosa AcquisitaMyasthaenia GravisOptic NeuritisRecessive Dystrophic Epidermolysis Bullosa
Updated Nov 8, 2026. Something wrong or missing? Report it on the ARGX page.
See ARGX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ARGX catalysts and pipeline →